Search

Savara Inc

Lezárt

SzektorEgészségügy

4.82 10.55

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

4.74

Maximum

4.88

Fő mutatók

By Trading Economics

Bevétel

-2.9M

-40M

Egy részvényre jutó nyereség

-0.16

Munkavállalók

70

EBITDA

-2.9M

-40M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+134.64% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 10.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-202M

972M

Előző nyitás

-5.73

Előző zárás

4.82

Savara Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. nov. 6. 21:02 UTC

Savara Inc. shares are advancing, showing a significant increase since Thursday's close, with unusually high trading volume despite earlier pulling back from a session high.

2026. nov. 5. 21:04 UTC

Correlated Moves

Savara Inc. shares fell sharply, reflecting a broader decline in the biotechnology sector, as the SPDR S&P Biotech ETF also experienced significant losses.

2026. nov. 4. 20:52 UTC

Savara Inc. shares fell sharply, remaining below their 20-day moving average amid unusually high market volume and significant fluctuations earlier in the session.

2026. nov. 3. 21:07 UTC

Savara Inc. shares are advancing, building on Monday's close, despite pulling back from an earlier session high amid overall modest market gains.

2026. nov. 2. 23:06 UTC

Savara Inc. shares advanced in after-market trading, gaining ground since Monday's close, following three consecutive sessions that finished lower.

2026. okt. 30. 20:08 UTC

Savara Inc. shares fell significantly, reflecting broader market weakness, and finished notably lower compared to Thursday's close.

2026. okt. 29. 20:06 UTC

Savara Inc. shares fell sharply as the broader market closed lower after an early peak.

2026. okt. 28. 20:02 UTC

Savara Inc. shares are advancing, diverging from a broader market downturn observed during Wednesday's session.

2026. okt. 27. 21:01 UTC

Savara Inc. shares declined modestly in after-market trading, remaining near the bottom of their range after a notable drop earlier in the session.

2026. okt. 26. 23:56 UTC

Savara Inc's shares advanced in after-market trading, reflecting a notable rise since Monday's close, though still below its 20-day moving average.

2026. okt. 23. 21:02 UTC

Savara Inc shares advanced in after-market trading, reaching a high shortly after the market closed before settling to a more modest gain.

2026. okt. 22. 20:07 UTC

News

Savara Inc's stock is declining after the company reiterated its Market Outperform rating and $10 price target, following new Molbreevi data presented at the CHEST conference.

2026. okt. 21. 23:16 UTC

Savara Inc is trading higher in after-market hours, gaining since Wednesday's close.

2026. okt. 20. 23:06 UTC

Savara Inc. shares advanced modestly in after-market hours, following a session that saw earlier peak gains before settling lower.

2026. okt. 19. 22:51 UTC

Savara Inc shares are moving higher in after-market trading, supported by an upward trend in the broader market, despite earlier session pullbacks.

2026. okt. 16. 22:26 UTC

Savara Inc shares traded lower in after-market hours, reflecting ongoing weakness amid broader market concerns over rising U.S. import and export prices.

2026. okt. 15. 23:06 UTC

Savara Inc's shares are advancing in after-market trading, gaining ground since Thursday's close, with a cumulative return peaking at just under 1.9%.

2026. okt. 14. 19:36 UTC

Savara Inc shares fell modestly on Wednesday, retracing from an early peak and remaining under pressure below their 20-day moving average.

2026. okt. 13. 20:13 UTC

Savara Inc shares advanced in after-market trading, continuing their upward trend since Tuesday's close, though still below the 20-day moving average.

2026. okt. 12. 19:36 UTC

Social Media

Savara Inc shares are declining, having pulled back from an earlier high in pre-market hours, and are currently below their 20-day moving average.

2026. okt. 9. 19:55 UTC

Social Media

JPMorgan sets a price target of $12 for Savara Inc, noting catalysts including anticipated UK approval in Q4 and a MAA in Q1 for molgramostim.

2026. okt. 8. 23:25 UTC

Savara Inc shares advanced during after-market hours on Thursday, settling at a solid gain.

2026. okt. 7. 20:01 UTC

News
Social Media

Savara Inc shares are trading sharply higher as JP Morgan initiated coverage with an Overweight rating and a $12 price target ahead of its PDUFA date.

2026. okt. 6. 20:00 UTC

Savara Inc shares fell, breaking a trend of higher daily closes, indicating a shift in momentum following Monday's close.

2026. okt. 2. 20:01 UTC

Savara Inc shares fell sharply, experiencing significant volatility and trading below their 20-day moving average amid high market volume.

2026. okt. 1. 19:46 UTC

Social Media

Savara Inc shares are trading lower as heightened short interest and increased volume coincide with the approach of its PDUFA date for molgramostim.

2026. szept. 30. 21:03 UTC

Social Media

Savara Inc shares are trading higher in after-market hours amid speculation of a short squeeze ahead of its PDUFA date for molgramostim, with a market cap of $1 billion.

2026. szept. 28. 20:02 UTC

Social Media

Savara Inc is trading higher amid notable social media activity and unusual options bets, with a PDUFA date set for November 22.

2026. szept. 25. 20:07 UTC

Savara Inc shares fell sharply, continuing the downward trend with a cumulative return in negative territory and remaining below its 20-day moving average.

2026. szept. 24. 19:46 UTC

Savara Inc is trading higher, having previously peaked before a slight retracement, though it remains below its 20-day moving average.

Társak összehasonlítása

Árváltozás

Savara Inc Előrejelzés

Célár

By TipRanks

134.64% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 11.333 USD  134.64%

Magas 16 USD

Alacsony 9 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Savara Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

6

Vétel

0

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat